Furthermore, a previous analysis of data from the cancer genome atlas showed that the presence of MITF-low/AXL-high cells (as also seen in our primed cell state) in drug-naive patient tumors was predictive of a shorter progression-free survival rate29. This evidence concerns the gene MITF and cancer.